Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

Semaglutide reduces vascular resistance and prevents fibrosis in kidneys of people with type 2 diabetes and chronic kidney disease, as shown by secondary outcomes.

• Why it matters: Understanding how semaglutide preserves kidney function is crucial for developing targeted treatments for diabetic kidney disease, yet its mechanisms remain unclear.
• What they did: A 52-week randomized trial compared semaglutide 1 mg weekly to placebo in 106 participants, using magnetic resonance imaging, kidney biopsies, and transcriptomic analyses to explore kidney-specific effects.
• The result: Findings suggest semaglutide may protect kidneys by lowering vascular resistance, preventing fibrosis, and enhancing endothelial cell health, offering insights into its protective mechanisms.